Cambridge, MA, United States of America

Sambasiva Rao

USPTO Granted Patents = 1 

Average Co-Inventor Count = 11.0

ph-index = 1


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Sambasiva Rao

Introduction

Sambasiva Rao is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of multifunctional binding proteins. His work focuses on advancing therapeutic options for proliferative disorders, including multiple myeloma.

Latest Patents

Sambasiva Rao holds a patent for "Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with Fc-engineering." This patent describes multifunctional binding proteins that consist of a first and a second antigen binding domain (ABD) along with an immunoglobulin Fc region or its variant. The first ABD specifically binds to human BCMA, while the second ABD binds to human NKp46. Additionally, the immunoglobulin Fc region is designed to bind to a human Fc-γ receptor. This innovation has potential applications in the treatment or prevention of proliferative disorders, including multiple myeloma.

Career Highlights

Throughout his career, Sambasiva Rao has demonstrated a commitment to advancing medical science through innovative research. His patent reflects his expertise in immunology and protein engineering, showcasing his ability to create solutions that address critical health challenges.

Collaborations

Sambasiva Rao has collaborated with notable colleagues, including Nicolas Gourdin and Laurent Gauthier. These partnerships have likely contributed to the successful development of his innovative binding proteins and their applications in therapeutic settings.

Conclusion

Sambasiva Rao's contributions to biotechnology, particularly through his patent on NK cell engagers, highlight his role as an influential inventor in the field. His work not only advances scientific knowledge but also holds promise for improving treatment options for patients with proliferative disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…